Published in Hepatitis Weekly, February 19th, 1996
The drug, bis-POM-9-(2-phosphonylmethoxyethly)adenine (bisPOM PMEA), is a prodrug that the body converts into its parent compound, PMEA or adefovir (code name GS 393). PMEA itself has poor oral bioavailability, but is exquisitely active against HIV in laboratory studies.
The drug's manufacturer, Gilead Sciences Inc., Foster City, California, has dubbed the new compound adefovir dipivoxil (code name GS 840).
Laboratory studies also showed that both drugs are active against...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.